Understand the source comparison
Subcutaneous vs Intranasal Administration and Bioavailability
Subcutaneous injection delivers approximately 85–90% bioavailability for P21, meaning nearly the entire administered dose reaches systemic circulation and crosses the blood-brain barrier via active transport mechanisms. Intranasal administration. Frequently ma
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous injection delivers approximately 85–90% bioavailability for P21, meaning nearly the entire administered dose reaches systemic circulation and crosses the blood-brain barrier via active transport mechanisms. Intranasal administration. Frequently marketed as more convenient. Achieves only 20–35% bioavailability because the peptide must traverse nasal mucosa and avoid enzymatic degradation in the nasal cavity before reaching the bloodstream. This isn't a minor difference: a 30mg subcutaneous dose delivers roughly the same brain exposure as 75–100mg intranasal, making subcutaneous injection both more cost-effective and more predictable.
- The injection itself is straightforward: P21 is typically supplied as lyophilised powder requiring reconstitution with bacteriostatic water at a 1:1 or 2:1 ratio (1mg peptide per 0.1mL water). Once reconstituted, store at 2–8°C and use within 28 days. Administer via 0.3mL to 0.5mL subcutaneous injection into abdominal fat tissue using an insulin syringe. The same technique used for semaglutide or other peptide protocols. Rotate injection sites to prevent lipohypertrophy.
- Our experience working with researchers in this space shows that administration route errors. Specifically, attempting intranasal delivery with peptides formulated for injection. Account for the majority of "P21 didn't work" reports. The peptide works, but only when bioavailability supports brain tissue concentrations high enough to activate BDNF pathways.